Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I-II Trial of Erlotinib in Higher Risk Myelodysplastic Syndrome

NCT01085838 is registered in ClinicalTrials.gov with Groupe Francophone des Myelodysplasies as lead sponsor.

NCT NCT01085838
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01085838 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I-II Trial of Erlotinib in Higher Risk Myelodysplastic Syndrome
Lead sponsor
Groupe Francophone des Myelodysplasies
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2010
Completion date
March 31, 2014
Enrollment
30 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndrome